High-affinity immunoglobulin epsilon receptor-bound Immunoglobulin E (FcεRI-bound IgE)

FcεRI-bound Immunoglobulin E (IgE) refers to the specific molecular state where IgE antibodies are tethered to the high-affinity FcεRI receptors on the surface of mast cells and basophils (Frontiers in Immunology, 2019). This complex serves as the primary sensor for allergens; when multivalent allergens cross-link these receptor-bound IgE molecules, they initiate a signaling cascade that leads to the rapid degranulation and release of inflammatory mediators such as histamine, proteases, and leukotrienes (Frontiers in Immunology, 2019). While established therapies like omalizumab primarily target free circulating IgE to prevent the formation of new complexes, the FcεRI-bound form is the target of next-generation 'dissociators' or 'disruptors' (Journal of Biological Chemistry, 2017). These agents, including designed ankyrin repeat proteins (DARPins) and low-affinity antibodies, are engineered to actively displace IgE from the receptor or promote the internalization of the complex without triggering cell activation (Journal of Immunology, 2019). By directly addressing the pre-existing sensitized state of effector cells, these therapies aim to provide faster clinical onset and improved outcomes for patients with severe allergic diseases like asthma and chronic spontaneous urticaria (ResearchGate, 2020).

Other names

IgE-FcεRI complexReceptor-bound IgESurface-bound IgEMast cell-bound IgE

Facilitated dissociation of IgE from the FcεRI receptor (Journal of Biological Chemistry, 2017), steric inhibition of allergen binding (Frontiers in Immunology, 2019), and induction of IgE/FcεRI complex internalization (Journal of Immunology, 2019).